Shared on 01 Nov 25
Fair value Increased 2.97%Quest Diagnostics' analyst fair value estimate has been raised from $191.56 to $197.25 per share. This change reflects analysts' upbeat outlook after strong quarterly results, improved profit margins, and continued momentum in core business trends.
Shared on 18 Oct 25
Fair value Increased 1.79%Analysts have raised their fair value estimate for Quest Diagnostics from $188.19 to $191.56 per share, citing ongoing stable end markets and improving revenue growth expectations. Analyst Commentary Recent street research has highlighted a mix of optimism and caution surrounding Quest Diagnostics.
Shared on 30 Apr 25
Fair value Increased 4.33%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Decreased 3.68%AnalystConsensusTarget has decreased revenue growth from 5.5% to 4.8%.
Shared on 16 Apr 25
Fair value Increased 0.57%AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.
Shared on 09 Apr 25
Fair value Increased 0.59%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 2.29%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 0.034%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 0.034%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Decreased 4.43%AnalystConsensusTarget has decreased profit margin from 11.6% to 10.4%.